Edition:
United Kingdom

People: Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

4.77USD
16 Aug 2019
Change (% chg)

$0.05 (+1.06%)
Prev Close
$4.72
Open
$4.75
Day's High
$4.84
Day's Low
$4.72
Volume
318,225
Avg. Vol
422,572
52-wk High
$5.02
52-wk Low
$1.29

Verwiel, Frank 

Dr. Frank A. G. M. Verwiel, M.D., is an Independent Director of Achillion Pharmaceuticals, Inc. With more than 25 years of experience in the pharmaceutical industry, Dr. Verwiel served as President, Chief Executive Officer and a member of the Board of Directors of Aptalis Pharma, Inc., a privately-held, specialty pharmaceutical company, which was acquired by Forest Laboratories, Inc. in February 2014. Prior to joining Aptalis Pharma, Inc., Dr. Verwiel held international senior management positions with Merck & Co., Inc., including as Vice President, Hypertension, Worldwide Human Health Marketing from June 2001 to May 2005. Dr. Verwiel was also Managing Director of Merck’s Dutch subsidiary from June 1996 to May 2001. Prior to his tenure at Merck, Dr. Verwiel had international leadership positions at Servier Laboratories, a pharmaceutical company, from 1988 until 1995. Since 2015, Dr. Verwiel has served as a director of Avexis, Inc., a publicly traded, clinical-stage gene therapy company. In August 2015, Dr. Verwiel was appointed as an observer of the Board of Directors of Bavarian Nordic A/S, a publicly traded biopharmaceutical vaccine company and was appointed as a Director on April 20, 2016. Dr. Verwiel is also Chairman of the Board of ObsEva SA, a publicly traded company developing drugs addressing conditions relating to women’s reproductive health, where he became a director in January 2016. In July 2017, Dr. Verwiel was appointed to the Board of Intellia Inc., a publicly traded gene editing company. From March 2012 to September 2014, Dr. Verwiel was a director of InterMune, Inc., a publicly traded biotechnology company that was acquired by Roche in 2014. Dr. Verwiel was also a member of the Board of Directors of the Biotechnology Industry Organisation (BIO) from February 2013 to April 2014. Dr. Verwiel holds an M.D. from Erasmus University, Rotterdam in The Netherlands and an M.B.A. from INSEAD, Fontainebleau in France.

Basic Compensation

Total Annual Compensation, USD 77,625
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 87,037
Fiscal Year Total, USD 164,662

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --